万泰生物：公司九价人乳头瘤病毒疫苗（大肠埃希菌）首次获得批签发证明

Core Viewpoint - The announcement indicates that Wantai Biological's subsidiary has received the production approval for the nine-valent HPV vaccine, marking its official market entry, which is expected to enhance the company's revenue and profit growth potential, strengthen its competitive position, and solidify its market status [1]. Group 1 - Wantai Biological's subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has obtained the "Biological Product Batch Release Certificate" from the China Food and Drug Inspection Institute for its nine-valent HPV vaccine [1]. - The approval signifies the first market launch of the nine-valent HPV vaccine product, which will enrich and optimize the company's product lineup [1]. - The introduction of this product is anticipated to create new revenue and profit growth points for the company, thereby enhancing its profitability and market competitiveness [1].